Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

3SBio Acquires China Rights to Numab Immunotherapy

publication date: Dec 17, 2021

3SBio (HK:1530) of Shenyang expanded its partnership with Zurich's Numab Therapeutics by acquiring China rights to Numab's multivalent mesothelin (MSLM)-targeting CD3 T cell engager, an immunotherapy. The candidate consists of four antibody variable domain fragments directed against MSLN, CD3 and human serum albumin. MSLN is commonly expressed in several types of tumor cells including mesothelioma, lung, biliary, ovarian, breast and pancreatic cancer. In 2019, 3SBio invested $15 million in Numab for options to develop up to five novel Numab immunotherapy candidates. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital